Corvus Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 15, 2022. The record date for the meeting was April 18, 2022, with 46,553,511 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals. A total of 35,495,934 shares were voted in person or by proxy. The results were as follows:
- Proposal 1 (Election of Directors): All three Class III nominees (Ian T. Clark, Elisha P. (Terry) Gould III, and Peter Thompson, M.D.) were elected to the Board of Directors.
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of the Named Executive Officers.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders selected a 1-year frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors, who will serve until the 2025 Annual Meeting.
- Confirm the engagement of PricewaterhouseCoopers LLC for the 2022 fiscal year audit.
- Note that 12,403,625 shares were recorded as broker non-votes across multiple proposals.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 28, 2022) for detailed background on the proposals.